Evoke Pharma Inc reports results for the quarter ended in September - Earnings Summary

Evoke Pharma

09/11/2022 22:50

* Evoke Pharma Inc  EVOK.OQ  reported a quarterly adjusted
loss
of 60 cents​​ per share for the quarter ended in September. The
lone analyst forecast for the quarter was for a loss of 66 cents
per share.
    * Revenue fell 10.5% to $832.00 thousand from a year ago;
analysts
expected $572.00 thousand. 
    * Evoke Pharma Inc's reported EPS for the quarter was a loss
of 60
cents​.
    * The mean earnings estimate of analysts had fallen by
about 10%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Evoke Pharma Inc shares had fallen by 13.9% this
quarter and
lost 75.6% so far this year.
    * The company reported a quarterly loss of $2.01 billion.
    * Wall Street's median 12-month price target for Evoke
Pharma Inc
is $63.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 10:50 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.66          -0.60          Beat
 Jun. 30 2022      -0.60          -0.71          Missed
 Mar. 31 2022      -0.48          -0.84          Missed
 Dec. 31 2021      -0.96          -0.72          Beat